Nicholas Company Inc. Acquires 127,210 Shares of Sanofi $SNY

Nicholas Company Inc. raised its holdings in shares of Sanofi (NASDAQ:SNY) by 10.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 1,397,265 shares of the company’s stock after buying an additional 127,210 shares during the period. Sanofi makes up approximately 1.1% of Nicholas Company Inc.’s portfolio, making the stock its 29th largest position. Nicholas Company Inc.’s holdings in Sanofi were worth $67,502,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SNY. Nuveen LLC bought a new position in shares of Sanofi during the 1st quarter worth approximately $177,831,000. Federated Hermes Inc. grew its stake in shares of Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after acquiring an additional 1,456,269 shares in the last quarter. OLD Mission Capital LLC bought a new position in shares of Sanofi during the 1st quarter worth approximately $48,938,000. Regal Partners Ltd grew its stake in shares of Sanofi by 102.3% during the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock worth $74,794,000 after acquiring an additional 782,838 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in shares of Sanofi by 15.1% during the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after acquiring an additional 425,597 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

SNY has been the subject of several analyst reports. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Sanofi has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Trading Down 0.7%

Shares of Sanofi stock opened at $50.58 on Friday. The business has a fifty day simple moving average of $48.69 and a two-hundred day simple moving average of $49.54. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a market capitalization of $124.20 billion, a price-to-earnings ratio of 11.85, a P/E/G ratio of 1.38 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter last year, the firm posted $2.25 EPS. The company’s quarterly revenue was down 7.5% on a year-over-year basis. Research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.